| Previous close | 8,419.00 |
| Open | 8,464.00 |
| Bid | 8,451.00 x 0 |
| Ask | 8,453.00 x 0 |
| Day's range | 8,430.00 - 8,577.00 |
| 52-week range | 5,871.00 - 9,537.09 |
| Volume | 1,011,233 |
| Avg. volume | 2,270,364 |
| Market cap | 111.15B |
| Beta (5Y monthly) | 0.26 |
| PE ratio (TTM) | 51.74 |
| EPS (TTM) | 163.70 |
| Earnings date | 05 Nov 2020 |
| Forward dividend & yield | 2.16 (2.57%) |
| Ex-dividend date | 13 Aug 2020 |
| 1y target est | 78.83 |
- Simply Wall St.
The Price Is Right For AstraZeneca PLC (LON:AZN)
AstraZeneca PLC's (LON:AZN) price-to-earnings (or "P/E") ratio of 67.7x might make it look like a strong sell right...
- Yahoo Finance
Coronavirus update: NY's Cuomo OKs sending students back to school as vaccine optimism rises
New York’s school districts will welcome students back into classrooms in the fall, Governor Andrew Cuomo announced on Friday, as the former coronavirus epicenter continues on its recovery.
- Reuters
Japan in deals with AstraZeneca, Novavax for COVID-19 vaccines
Japan plans to buy AstraZeneca Plc's <AZN.L> experimental COVID-19 vaccine and fund a local company to manufacture Novavax's <NVAX.O> vaccine candidate, ramping up its stockpile plan as it battles surging infections. Japan will order 120 million doses of the experimental vaccine developed by the British pharmaceutical company, beginning with 30 million doses by March next year. Separately, Takeda Pharmaceutical <4502.T> said on Friday it would manufacture and sell up to 250 million doses of Novavax's COVID-19 vaccine candidate every year in Japan, with funding support from the government.
